TY - JOUR
T1 - Percutaneous ethanol sclerotherapy is a promising treatment for recalcitrant angiolymphoid hyperplasia with eosinophilia
AU - Galili, E.
AU - Levi, A.
AU - Lapidoth, M.
AU - Barzilai, A.
AU - Hodak, E.
AU - Rimon, U.
N1 - Publisher Copyright:
© 2021 British Association of Dermatologists
PY - 2022/3
Y1 - 2022/3
N2 - Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare benign vascular proliferation, which manifests as characteristic red nodules and papules, mostly located on the scalp and periauricular regions. Patients seek treatment for both aesthetic and functional reasons, as lesions may ulcerate, bleed and itch. Many therapeutic approaches have been reported, with variable success, and relapse remains a troublesome issue. The aim of this study was to report our experience treating ALHE using percutaneous ethanol sclerotherapy (PES). We present a retrospective case series of three patients treated with PES (1–2 treatment sessions each). All patients had tried and failed other treatments prior to this intervention, but following PES treatment, all patients demonstrated significant improvement, which was sustained at follow-up (range 8–17 months after first treatment). Adverse effects were tolerable and transient. This case series demonstrates PES as a promising treatment for recalcitrant ALHE.
AB - Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare benign vascular proliferation, which manifests as characteristic red nodules and papules, mostly located on the scalp and periauricular regions. Patients seek treatment for both aesthetic and functional reasons, as lesions may ulcerate, bleed and itch. Many therapeutic approaches have been reported, with variable success, and relapse remains a troublesome issue. The aim of this study was to report our experience treating ALHE using percutaneous ethanol sclerotherapy (PES). We present a retrospective case series of three patients treated with PES (1–2 treatment sessions each). All patients had tried and failed other treatments prior to this intervention, but following PES treatment, all patients demonstrated significant improvement, which was sustained at follow-up (range 8–17 months after first treatment). Adverse effects were tolerable and transient. This case series demonstrates PES as a promising treatment for recalcitrant ALHE.
UR - http://www.scopus.com/inward/record.url?scp=85117300712&partnerID=8YFLogxK
U2 - 10.1111/ced.14940
DO - 10.1111/ced.14940
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34559911
AN - SCOPUS:85117300712
SN - 0307-6938
VL - 47
SP - 568
EP - 572
JO - Clinical and Experimental Dermatology
JF - Clinical and Experimental Dermatology
IS - 3
ER -